Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Co-Diagnostics Inc.

Co-Diagnostics (($CODX)) has held its Q4 earnings call. Read on for the main highlights of the call. Co-Diagnostics’ latest earnings call painted a...

Co-Diagnostics Earnings Call: Pipeline Progress, Cash Strain

Austin, Texas, United States, March 20th, 2026, FinanceWire Co-Diagnostics&nbsp;(NASDAQ:CODX)&nbsp;announced that its Indian joint venture,&nbsp;Co...

Co-Diagnostics (NASDAQ: CODX) Expands CoSara Distribution Territory Across South Asia

Co-Diagnostics ( ($CODX) ) has issued an announcement. On March 9, 2026, Co-Diagnostics, Inc. received formal notice from Nasdaq that it had regain...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CODX	$1.42	0.00%	76.30K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CODX	$1.42	0%	76.30K
3
4
5
6

CODX

CODX

Get Co-Diagnostics Inc. Data in Excel

Get Co-Diagnostics Inc. Data in Excel